Lilly Launches First-in-Class Phase III Trial of GLP-1/GIP/GCGR Triple Agonist Retatrutide for Chronic Low Back Pain in Overweight and Obese Patients

Local time 6On the 24th day of the month, Eli Lilly and Company registered a study on the ClinicalTrials.gov website to evaluateRetatrutide（Retatrutide、LY3437943）InA Phase III Clinical Study on the Efficacy and Safety in Patients with Obesity or Overweight and Chronic Low Back Pain（TRIUMPH-7, Registration Number:NCT07035093）。

Insight database shows that this is the world's firstGLP1R/GIPR/GCGR Triagonist in Phase III Clinical Trial for Pain.

Source:ClinicalTrials.gov Official Website

TRIUMPH-7 is a randomized, double-blind, placebo-controlled Phase III clinical trial designed to evaluate once-weeklyEfficacy and Safety of Retatrutide in Patients with Obesity or Overweight and Chronic Low Back PainLasting 80 Weeks, scheduled to start in June 2025 and be completed in September 2027.

The study is expected to enroll586 subjects, randomly assigned to receiveRetatrutide and Placebo Treatment. MainThe key point isChange in pain intensity compared to baseline, percentage change in weight relative to baseline. Secondary endpoints includeStrong PainThe number of participants with reduced degrees, the number of participants who lost weight, etc.

Retatrutide is a GLP1R/GIPR/GCGR Triagonist, which is the fastest progressing globally. Currently, research is being conducted on obesity, type 2 diabetes, and secondary prevention of cardiovascular events.Phase III clinical trials for indications such as obstructive sleep apnea.

Source: Insight Database

Insight database shows,There are 17 similar products under development in China., ZX2021 (Zhongxin Pharmaceuticals), UBT251 (United Laboratories/Novo Nordisk), and MWN101 (Minwei Biotech) have all advanced to Phase II clinical trials.

Cover Source:Enterprise Logo/Zcool Hello

Disclaimer:This article is for information sharing only, and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment plans. If you have any needs, please consult and contact正规医疗机构.

Editor: Crescent

PR Article Collaboration: WeChat insightxb